By Tucker, Miriam E.
Clinical Psychiatry News , Vol. 32, No. 12
ORLANDO, FLA. -- Improved glycemic control appears to improve working memory in patients with type 2 diabetes, Mark W. J. Strachan, M.D., reported at the annual scientific sessions of the American Diabetes Association.
A relatively large body of evidence suggests that type 2 diabetes is associated with cognitive impairment and decline over time and a two- to threefold elevated risk for both vascular dementia and Alzheimer's disease. Yet few studies have examined the impact of improved glycemic control on cognitive function in patients with type 2 diabetes, said Dr. Strachan of Western General Hospital and the University of Edinburgh, Scotland.
This prospective evaluation, funded by GlaxoSmithKline and conducted at 19 U.S. centers, involved 141 patients aged 45-75 years with type 2 diabetes for an average duration of 6.6 years. All subjects were taking metformin and another oral hypoglycemic agent, had achieved hemoglobin [A.sub.1c] levels of 8% or lower, had a score of 27 or above on the Mini-Mental State Examination, and had no current symptoms of depression. Subjects continued their usual doses of metformin, but the other oral agent was withdrawn during an 8-week period prior to randomization to either rosiglitazone maleate or glyburide. The doses of those two agents were titrated to achieve a target fasting blood glucose level below 140 mg/dL, Dr. …